Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to Stratistics MRC, the Global Antiviral market is accounted for $42.65 billion in 2016 and is expected to reach $63.11 billion by 2022 growing at a CAGR of 5.8%. Increased count of people across the globe affecting from influenza, respiratory syncytial virus and epidemic of viral infections had given market a prudential base for the growth. Strong R&D and newer & advance formulations in the antiviral drugs market are expected to drive the market. However, high risk of failure and huge cost of R&D are hampering the market.
HIV antivirals segment among applications is expected to dominate the market due to increase in prevalence of HIV infections, and due to growing awareness among people. Moreover, generic drugs segment is expected to witness lucrative growth over the forecast period on account of favorable government regulations. North American market is expected to dominate the global market. However, Asia Pacific is estimated to be the fastest growing region due to growing economies and increased healthcare expenditure in the region.
Some of the key players of the Antiviral Drugs market include Abbott Laboratories, AbbVie, Inc., Aurobindo Pharma, Bristol-Myers-Squibb, Cipla, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, GlaxoSmithKline plc., Johnson and Johnson, MedImmune/AstraZeneca, Merck & Co., Mylan N.V., Roche Diagnostics, Schering-Plough and Teva Pharmaceutical Industries Ltd.
Applications Covered:
• Hepatitis-B antivirals
• Hepatitis-C antivirals
• Herpes virus
• HIV antivirals
• Influenza
• Other Applications
o Pneumonia
o Flu
End-Users Covered:
• Ambulatory Surgical Centers
• Clinics
• Hospitals
Distribution Channels covered:
• Hospital Pharmacy Store
• Online Pharmacy
• Retail Pharmacy Store
Product Types Covered:
• Generic Drugs
• Branded Drugs
Action Mechanisms covered:
• Nucleotide polymerase inhibitor
• Protease inhibitors
• Reverse transcriptase inhibitors
• Other Action Mechanisms
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt
What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
HIV antivirals segment among applications is expected to dominate the market due to increase in prevalence of HIV infections, and due to growing awareness among people. Moreover, generic drugs segment is expected to witness lucrative growth over the forecast period on account of favorable government regulations. North American market is expected to dominate the global market. However, Asia Pacific is estimated to be the fastest growing region due to growing economies and increased healthcare expenditure in the region.
Some of the key players of the Antiviral Drugs market include Abbott Laboratories, AbbVie, Inc., Aurobindo Pharma, Bristol-Myers-Squibb, Cipla, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, GlaxoSmithKline plc., Johnson and Johnson, MedImmune/AstraZeneca, Merck & Co., Mylan N.V., Roche Diagnostics, Schering-Plough and Teva Pharmaceutical Industries Ltd.
Applications Covered:
• Hepatitis-B antivirals
• Hepatitis-C antivirals
• Herpes virus
• HIV antivirals
• Influenza
• Other Applications
o Pneumonia
o Flu
End-Users Covered:
• Ambulatory Surgical Centers
• Clinics
• Hospitals
Distribution Channels covered:
• Hospital Pharmacy Store
• Online Pharmacy
• Retail Pharmacy Store
Product Types Covered:
• Generic Drugs
• Branded Drugs
Action Mechanisms covered:
• Nucleotide polymerase inhibitor
• Protease inhibitors
• Reverse transcriptase inhibitors
• Other Action Mechanisms
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt
What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
